Table 1.

Lists of various potential new biomarkers and implication in clinical practice.

Biomarkers in aBC	Potential use in clinical practice	References
PLR	High PLR correlate to worse OS	(22)
NLR	High NLR correlate to worse OS and DFS	(34, 35)
MLR	High MLR correlate to worse OS (especially in TNBC) (p = 0.01351, p= 0.00256)	(52, 57)
Lymphopenia	Predictor of increased risk of progression and worse OS	(45, 46)
Pro-tumor circulating macrophages	M2 in blood of BC patients are associated with advanced stages	(60)
MDSCs	Enriched MDSCs in blood of BC patients can correlate with poor prognosis and metastatic extension	(79, 80)

M2, pro-tumors macrophages; MDSCSs, myeloid-derived suppressor cells; PLR, platelet-lymphocytes ratio; MLR, monocyte-lymphocyte ratio; NLR, neutrophil-lymphocyte ratio; OS, overall survival; DFS, disease free survival.